



AGILE FALCON STRATEGIC GROUP

6th

DDSS



OCTOBER 8TH-9TH

DIGITALLY

Day 1

8 : 50 - 9 : 00 **Welcome Address**

Stream 1 Target Identification & Validation

9 : 00 - 9 : 20



Keynote 01
Torsten Hoffmann
Senior Vice President Drug Discovery at Taros Chemicals
Optimization & identification of novel targets

9 : 20 - 9 : 40



Keynote 02
Sebastian Nijman
Co-Founder & CSO at Scenic Biotech
Harnessing genetic modifiers as therapeutic targets

Stream 2 Novel Drug Design Approaches

9 : 40 - 10 : 00



Keynote 03
Hasane Ratni
Expert Scientist, Project Team Leader at Roche
Structure-Activity Relationships in Drug Design

10 : 00 - 10 : 20



Keynote 04
Jean-François Ginglinger
CSO at Temisis
How regulating the target *NFKB1Z*/I κ B ζ results in very high efficacy in alleviating psoriasis symptoms

Stream 3 Artificial Intelligence & Machine Learning

10 : 20 - 10 : 40



Keynote 05
Michael Thormann
CEO at Origenis
Re-imaging Drug Discovery through AI

10:40 - 11:00



Keynote 06
Remko van Leeuwen
CEO at Madam Therapeutics
How AI techniques has helped us in shaping our portfolio of antimicrobial compounds

Stream 4 Drug Discovery Innovations & Technologies

11 : 00 - 11 : 20



Keynote 07
Thorsten Thormann
VP - Research at LEO Pharma
Targeting protein-protein interactions with small molecule drugs PPIs in immune disease

11: 20 - 11 : 40



Keynote 08
Bernd van Buuren
Co-Founder & CEO at Protinhi Therapeutics
Broad spectrum antivirals as early interventions against viruses posing pandemic threats

11 : 40 - 1 : 00 **Meeting & Networking**

Day 2

8 : 50 - 9 : 00 **Welcome Address**

Stream 5 Medicinal Chemistry & Drug Design

9 : 00 - 9 : 20

Keynote



Leif Håkansson
CSO at Canimguide Therapeutics

Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities



9 : 20 - 9 : 40

Keynote



Werngard Czechtizky
Senior Director, Head Medicinal Chemistry, IMED RIA at AstraZeneca
Developing alternative modalities as the therapeutics approaches in drug discovery



Stream 6 Innovations in HTS & compound profiling

9 : 40 - 10 : 00

Keynote



Kamal Azzaoui
CEO/Co-founder at Saverna Therapeutics
Targeting non-coding functional RNAs



10 : 00 - 10 : 20

Keynote



Pascal Mayer
CEO at Alphanosos
AI for rapid anti-infective discovery and response to pandemics



Stream 7 Preclinical Operations

10 : 20 - 10 : 40

Keynote



Sandra Robelet Karakotchian
Scientific Director / Business Developer at SYNCROsome - Preclinical Efficacy CRO
Advances in preclinical approaches to Chagas disease drug discovery



10 : 40 - 11 : 00

Keynote



Auke van Heel
CEO, Co-Founder at Omnicin Therapeutics
Increasing the Antimicrobial Activity of Lipid II targeting antibiotics against gram negative pathogens



Stream 8 Strategic partnerships & outsourcing

11 : 00 - 11 : 20

Keynote



Wolfgang Fecke
Director General
Tool compounds and drug candidates from the European chemical biology infrastructure EU-OPENSREEN



11 : 20 - 11 : 40

Keynote



Patrizia Anna d'Alessio
Founder & CEO at AISA Therapeutics
SARS-Cov-2 infection as model for the aging



11 : 40 - 1 : 00 **Meeting & Networking**

1 : 00 - 1 : 15 Closing Event